Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Delisting risk
confidence 92%
filed 2026-06-16
EX-99.1
Biophytis announces temporary suspension of trading of its shares on Euronext Growth Paris effective June 15, 2026, due to non-publication of the annual financial report for fiscal year 2025. The suspension results from an "operational delay in the preparation of financial statements" and trading is expected to resume only after publication of the audited annual report (expected no later than end of July 2026). This is a material delisting risk event — a failure to satisfy continued listing requirements (timely filing of annual financial statements) that has triggered an exchange-imposed trading suspension, directly threatening the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear disclosure of shareholder voting results from Latch's June 10, 2026 annual meeting of stockholders, filed under Item 5.07. The filing presents tabulated voting outcomes for three proposals: election of six directors, ratification of BDO USA as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-16
Item 8.01
The filing discloses that the HSR waiting period for the previously announced merger between Esperion and ArchiMed SAS (through Essence Parent Inc. and MergerCo) expired on June 15, 2026. This represents a material milestone in the completion of a change-of-control transaction, with the Company surviving as a wholly-owned subsidiary of Parent. The disclosure explicitly references the Merger Agreement entered into on May 1, 2026, and notes that stockholder approval remains a closing condition, with the special meeting scheduled for July 8, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from ExlService's 2026 Annual Meeting of Stockholders. The filing reports the final vote tallies for three proposals: election of seven board directors (all elected), ratification of Deloitte & Touche LLP as auditor (approved), and Say-on-Pay advisory vote (approved). The detailed voting results with For/Against/Abstain/Broker Non-Vote counts are the core content of the filing.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-16
The 6-K discloses the results of Ardmore Shipping's 2026 Annual Meeting of Shareholders held on June 15, 2026, reporting the election of three Class I Directors (Mats Berglund, Kirsi Tikka, and Gernot Ruppelt) with specific vote tallies for and withheld. This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, which is material to investors as it reflects the composition of the board of directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-16
Item 5.02
The disclosure centers on an Amended and Restated Employment Agreement with Chad Cowan, Ph.D., the Chief Scientific Officer, modifying his compensation structure to part-time status with a reduced annual salary of $296,150 and pro-rated performance-based bonus eligibility. While the agreement also addresses termination provisions, the principal disclosed action is a compensatory arrangement modification for a named executive officer, which falls squarely within exec_compensation rather than exec_departure (no departure occurred) or exec_appointment (no new role assumed).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This is a clear disclosure of shareholder voting results from John Marshall Bancorp's Annual Meeting of Shareholders held on June 16, 2026. The filing reports the outcomes of two proposals: (1) election of eight directors with detailed vote tallies for each nominee, and (2) ratification of Yount, Hyde & Barbour, P.C. as the independent auditor. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms the composition of the board and auditor appointment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-16
Item 5.02
Shareholders approved an amended and restated 2013 Performance Incentive Plan that increases the share pool by 8.8 million shares (from 48.0 to 56.8 million) and extends the plan expiration to 2036, materially expanding equity award capacity for officers, directors, and employees.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Norwegian Cruise Line Holdings held its annual general meeting on June 11, 2026, with shareholders voting on six proposals including election of three Class I directors, advisory approval of executive compensation, auditor ratification, and approval of a board declassification proposal.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
The filing discloses a delisting notice from Nasdaq under Item 3.01, specifically that MaxCyte's stock fell below the $1.00 minimum bid price requirement for 30 consecutive trading days, triggering non-compliance with Nasdaq Listing Rule 5450(a)(1). Although the company subsequently regained compliance by June 9, 2026, the initial delisting risk and the regulatory process itself are material events that would affect investor assessment of the company's listing status and market viability.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 35%
filed 2026-06-16
Item 8.01
Safehold Inc. disclosed a private placement of $225 million in Senior Notes under a note purchase agreement, offered in reliance on Section 4(a)(2) of the Securities Act without registration. While this is a debt issuance rather than an equity issuance, the unregistered nature and private placement structure align with the dilutive_issuance category's focus on unregistered securities sales. However, the event is fundamentally a debt financing, not an equity dilution, which creates genuine uncertainty about the best classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on June 11, 2026, including: (1) election of seven board members with vote tallies for each director; (2) non-binding advisory approval of named executive officer compensation (28,547,283 shares for); (3) shareholder approval of annual frequency for future say-on-pay votes; and (4) ratification of Ernst & Young LLP as independent auditor (29,842,514 shares for). These are standard shareholder vote results that materially inform investors about board composition and governance decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 2.01
Assertio Holdings completed a tender offer and merger on June 16, 2026, whereby the company became a wholly owned subsidiary of Parent. The transaction involved acceptance of 4,286,488 shares (66.32% of outstanding) in the tender offer, followed by a Section 251(h) merger converting all remaining shares into cash merger consideration, constituting a material change of control.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
Assertio Holdings notified Nasdaq to halt trading and delist its shares effective June 16, 2026, in connection with the merger closing. The company intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-16
Item 5.02
Six directors (Heather L. Mason, Sravan K. Emany, Sigurd C. Kirk, William T. McKee, David M. Stark, and Mark L. Reisenauer) voluntarily resigned as directors, and all officers ceased service, in connection with the merger transaction.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 65%
filed 2026-06-16
Item 2.04
The merger triggered a Fundamental Change and Make-Whole Fundamental Change under the company's convertible notes indenture, accelerating conversion rights and granting noteholders repurchase rights at 100% of principal plus accrued interest on $40 million in convertible notes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 5.03
The Company's certificate of incorporation and bylaws were completely amended and restated pursuant to the terms of the Merger Agreement at the Effective Time, reflecting the completed merger transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 filing discloses the results of Battalion Oil Corporation's June 11, 2026 Annual Meeting of Stockholders, including voting outcomes for two proposals: election of four directors (Jonathan D. Barrett, Gregory S. Hinds, William D. Rogers, and Matthew B. Steele) and ratification of Deloitte & Touche LLP as independent auditor. The tabulated vote counts for each proposal are the core disclosure, making this a classic shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Elutia Inc. held its annual meeting of stockholders on June 11, 2026, at which shareholders voted on five proposals: election of two Class III directors (David Colpman and Kevin Rakin), ratification of PricewaterhouseCoopers LLP as auditor, approval of the First Amendment to the 2020 Incentive Award Plan, advisory approval of named executive officer compensation, and advisory vote on say-on-pay frequency. All five proposals passed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-16
Item 1.01
Huntsman Corporation entered into an Agreement and Plan of Merger with Olin Corporation on June 15, 2026, providing for an all-stock merger of equals transaction at an exchange ratio of 0.5476 shares of Olin Common Stock per Huntsman share. The filing also discloses a concurrent voting and support agreement executed by Peter Huntsman and affiliated entities to vote their shares in favor of the merger and against competing proposals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This 8-K Item 5.07 discloses the final results of Adagio Medical's 2026 Annual Meeting of Stockholders held on June 16, 2026, including voting outcomes for two proposals: election of two directors (Orly Mishan and Sean Salmon, both elected) and ratification of WithumSmith+Brown, PC as independent auditor (ratified with overwhelming support). The disclosure provides vote counts, shares outstanding, and quorum information, which is the standard format for shareholder vote results required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 1.01
Antero Resources established a $1.65 billion commercial paper program on June 16, 2026, creating a material direct financial obligation. The program includes dealer agreements and is intended for general corporate purposes including acquisitions and debt repayment, representing a significant financing commitment affecting the company's liquidity and capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 8.01
The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure reports the final voting results from Gyre Therapeutics' June 10, 2026 Annual Meeting of Stockholders, including election of directors (David M. Epstein and Dan Weng), non-binding advisory vote on executive compensation, ratification of Grant Thornton Zhitong as independent auditor, and approval of Series B Preferred Stock conversion. The filing presents tabulated vote counts for each proposal, which is the core content of a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-16
Item 8.01
The filing discloses three lawsuits challenging the proposed merger transaction filed in New York Supreme Court (Phillips v. Green Dot, Richardson v. Green Dot, and Zaccagnino v. Brewster), plus demand letters from purported stockholders alleging disclosure deficiencies in the proxy statement/prospectus. Although the company denies merit and made supplemental disclosures to mitigate litigation risk, the existence of multiple shareholder class-action-style challenges to a material M&A transaction constitutes material litigation that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-16
Item 2.01
Kennedy-Wilson Holdings completed a merger with a Consortium on June 16, 2026, in which common stockholders received $10.90 per share in cash consideration (approximately $1.6 billion total), with $1.3 billion in debt financing and $1.8 billion in senior notes issued to fund the transaction and redeem existing debt. The merger resulted in a change of control, conversion of all equity awards to cash, replacement of the board of directors, and modification of the company's governing documents.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-16
Item 3.01
Following completion of the merger, Kennedy-Wilson requested and obtained suspension of trading of its common stock on the NYSE, and initiated delisting from the NYSE and deregistration under Section 12(b) of the Exchange Act via Form 25, with intent to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-16
EX-99.1
This is a commercial fleet update disclosing May 2026 operations: 100% fleet utilization generating $713,000 in monthly charter revenue, secured contracted revenue exceeding $8.4 million for 2026, and the April 2026 sale of M/T Wonder Mimosa generating a $6.7 million gain. While the sale itself could be classified as a financial event (asset disposition), the disclosure is framed as an operational update covering fleet utilization, charter rates, and revenue visibility rather than a discrete M&A or financial transaction announcement. The material gain on sale and secured revenue visibility would affect investor assessment of near-term cash flow and earnings.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
VirnetX held its 2026 Annual Meeting of Stockholders with shareholder votes on multiple proposals: election of Class I directors (Kendall Larsen and Gary W. Feiner), ratification of auditor Farber Hass Hurley LLP, advisory approval of named executive officer compensation, and approval of an amendment to the 2013 Equity Incentive Plan increasing the share reserve by 1,000,000 shares. Vote tallies for each proposal are disclosed with results for votes for, against, withheld, abstentions, and broker non-votes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-16
Item 7.01
The filing discloses a press release highlighting five gene therapy programs targeting inherited retinal diseases. This is a material corporate development disclosure that does not fit neatly into the standard taxonomy categories—it is neither an earnings release, M&A activity, executive change, nor litigation. For a biotech company, disclosure of multiple gene therapy programs represents material pipeline information that would affect investor assessment of the company's prospects and competitive position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure reports the results of Thryv Holdings' annual stockholder meeting held on June 11, 2026, including the election of two Class III directors (John Slater and Joseph A. Walsh), ratification of Grant Thornton LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies for each proposal are the core content of the filing, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-16
Item 1.01
CarParts.com entered into a material $25 million asset-based revolving credit facility with First Business Specialty Finance on June 15, 2026, secured by substantially all company assets. This represents a significant financing transaction that materially affects the company's capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 45%
filed 2026-06-16
Item 1.02
CarParts.com terminated its JPM Credit Facility, which typically signals a covenant breach, default, or financial distress event. The termination of the prior credit facility is material and suggests underlying financial stress, though the precise nature of the termination—whether voluntary, forced by breach, or consensual—cannot be definitively determined from the available disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
Ingersoll Rand held its Annual Meeting of stockholders on June 11, 2026, with voting results on four proposals: election of ten directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the 2026 Omnibus Incentive Plan.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-16
This is a Capital Markets Day announcement disclosing Equinor's strategic plan through 2030, including production growth targets (150,000 boe/d increase to 2.3M boe/d), capital allocation guidance (USD 12B annual capex), and cash flow projections (30% CFFO growth, USD 40B+ free cash flow 2026-2030). While it includes capital distribution elements (share buyback doubling to USD 3B and dividend growth guidance), the primary substance is a comprehensive operational and strategic business plan with material forward-looking guidance on production, investment, and returns that would affect a reasonable investor's assessment of the company's direction and value creation potential.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-16
Item 8.01
AutoZone announced a $1.5 billion share repurchase authorization, which is a material capital allocation decision affecting shareholder value and the company's financial position. While share repurchases are routine for mature companies, the magnitude and explicit Board authorization make this material to investors. This does not fit neatly into the more specific event categories (it is not an earnings release, M&A activity, executive change, or financial restatement), so "other_material" is the appropriate classification.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 98%
filed 2026-06-16
EX-99.1
The press release announces the successful closing of a $200 million private placement offering of 7.00% Senior Unsecured Notes due June 16, 2031. This is a material creation of a new direct financial obligation. The company explicitly states it will use proceeds to repay existing indebtedness and for general corporate purposes, and the offering was underwritten by multiple major financial institutions, confirming the materiality and significance of this debt issuance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-16
EX-99.1
This exhibit is a corporate presentation detailing Evogene's AI-driven drug and agrochemical discovery platform (ChemPass AI) and its pipeline collaborations. It discloses material operational and strategic developments including: (1) expanded collaboration with Google Cloud (initiated Feb. 2026) to integrate advanced AI agents into the discovery platform; (2) multiple pharma collaborations for oncology, metabolic disease, and immunology programs; (3) agrochemical pipeline progress including wheat blotch fungicide candidate (APTF-1) showing 18-month development timeline and strong in vivo efficacy. While the presentation emphasizes technology capabilities and market opportunity rather than discrete transactional events, the disclosed collaborations, pipeline advancement, and strategic partnerships constitute material operational developments affecting the company's business prospects and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-16
EX-99.1
This press release announces a strategic partnership between Perion and Best Buy Canada to power a programmatic digital-out-of-home (DOOH) retail media network. The disclosure emphasizes market expansion into the high-growth retail media vertical, full-stack technology adoption (Ad Server, SSP, Header Bidding), and yield optimization benefits. While not a discrete M&A transaction, the partnership represents a material operational and strategic business development that expands Perion's footprint in retail media and demonstrates its ability to win enterprise-level mandates, supporting the company's "Perion One" strategy for sustainable, infrastructure-level revenue streams.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 98%
filed 2026-06-16
ICL Group completed a private offering of $800 million aggregate principal amount of senior unsecured notes due 2036, carrying a 6.036% coupon. The press release explicitly announces the "Completion of Senior Notes Offering" and details the terms, pricing, covenants, and credit ratings (BBB- by S&P and Fitch). This is a material creation of direct financial obligation under Item 2.03 of the 8-K taxonomy, and the $800 million principal amount is clearly material to a reasonable investor assessing the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-16
EX-99.1
YY Group announced completion of a US$20 million At-The-Market (ATM) equity offering program, raising gross proceeds with net proceeds of approximately US$19.1 million after sales commissions and expenses. ATM offerings are unregistered equity issuances that dilute existing shareholders. The company explicitly states the program is now "concluded" with "no further share sales" under this facility, confirming full utilization of the offering capacity. This is a material capital-raising event affecting shareholder equity.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-06-16
EX-99.1
GigaMedia announces conversion of US$12.37 million in Aeolus convertible notes into 719.09 million preferred shares, increasing its ownership stake to 33.35% and triggering a change in accounting treatment from available-for-sale to equity method. This is a material financial transaction involving a significant investment position and accounting reclassification, but does not fit the specific categories of debt issuance, dilutive issuance, or M&A activity—it is a conversion and settlement of an existing investment instrument, best classified as a material financial event outside the named categories.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-06-16
EX-99
Exhibit 99.1 discloses UMC's disposal of 1,174,694 shares of Novatek Microelectronics Corporation through conversion of zero-coupon exchangeable bonds due 2026, generating a gain of $386,963,843 NTD to retained earnings. This is a material asset disposition affecting the company's investment portfolio (42.27% of total assets, 57.85% of equity). Exhibit 99.2 is a routine monthly report of insider trading and pledge activity with no changes reported, which is administrative. The primary material event is the Novatek share disposal in 99.1.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-16
Item 7.01
Fiserv announced commencement of a tender offer to repurchase approximately $1.5+ billion in outstanding senior notes (5.150% Notes due 2027 and 4.400% Notes due 2049), contingent on proceeds from a concurrent euro-denominated senior notes offering. This is a material debt refinancing/capital structure event that does not fit neatly into the standard M&A or covenant-breach categories—it is a voluntary debt tender offer with financing conditions, disclosed under Item 7.01 (Regulation FD Disclosure) rather than Item 1.01 or 2.04.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-16
Item 7.01
Olin Corporation and Huntsman Corporation announced a proposed all-stock merger of equals transaction pursuant to an Agreement and Plan of Merger entered into on June 15, 2026. The disclosure explicitly states this is a "proposed combination" and describes the merger agreement, making this a material M&A activity event. The joint press release and investor presentation attached as exhibits document the entry into this material acquisition/merger transaction.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-16
EX-99.1
NovaBridge announced FDA Fast Track Designation for givastomig in first-line HER2-negative metastatic gastric cancer, a significant regulatory milestone that accelerates development and review. While not a discrete M&A, financing, or executive event, this regulatory achievement materially advances the company's clinical development pathway and would affect a reasonable investor's assessment of the drug candidate's prospects. The designation enables more efficient progress toward a registrational Phase 3 trial and potential accelerated approval, representing a material operational and strategic advancement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-16
Item 2.02
The filing discloses financial results for the first fiscal quarter ended May 2, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is material to investors as it provides periodic financial performance data essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-16
Item 5.02
The disclosure centers on the appointment of Bradley J. Pickard as a Class II director to FreightCar America's Board, effective June 10, 2026, with the Board size increasing to nine directors. This is a clear executive appointment event. While the section also mentions that Mr. Pickard will receive compensation "in accordance with the Company's non-executive director compensation policy," the principal disclosed action is the appointment itself, not a compensatory arrangement modification. The appointment is material as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-16
Item 5.07
This Item 5.07 disclosure presents the final voting results from Vital Farms' June 10, 2026 annual meeting of stockholders, covering three proposals: election of directors (Russell Diez-Canseco and Kelly Kennedy), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are the core content of the filing, matching the shareholder_vote_results event type precisely.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-16
Item 7.01
The Item 7.01 disclosure references entry into a "Purchase Agreement" and a "Transaction" announced via press release on June 16, 2026, with a Hong Kong Stock Exchange filing. While the specific nature of the transaction is not detailed in this excerpt, the language "entered into the Purchase Agreement" and formal Hong Kong regulatory filing suggest a material M&A or significant commercial transaction. However, without explicit confirmation of acquisition/disposition language or financial terms in this section alone, and given the vague reference to "the Transaction," the most defensible classification is other_material rather than ma_activity, though ma_activity remains plausible if the full press release (Exhibit 99.1) confirms acquisition or disposition activity.
View raw filing on EDGAR →